Neurocrine Biosciences (NBIX) is in focus after new CRENESSITY data at ENDO 2026 highlighted hormone normalization in classic CAH due to 11ß hydroxylase deficiency, alongside two-year cardiometabolic and bone health outcomes in adults.

At a share price of $158.29, Neurocrine Biosciences has given investors a 23.97% 90 day share price return and a 25.08% 1 year total shareholder return, pointing to momentum that has built alongside ENDO 2026 data and other recent product updates.

If CRENESSITY and INGREZZA have caught your attention, it can be useful to see what else is happening across healthcare AI and specialty treatments by scanning 41 healthcare AI stocks

So with Neurocrine Biosciences posting double digit revenue and net income growth alongside fresh CRENESSITY and INGREZZA data, is the current US$158.29 share price leaving meaningful upside on the table, or is it already reflecting years of future growth?

Most Popular Narrative: 18% Undervalued

With Neurocrine Biosciences last closing at $158.29 against a narrative fair value of $192.88, the gap reflects how analysts are weighing its rare disease and neurology portfolio against execution risks under a 7.11% discount rate.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Want to understand why this narrative thinks Neurocrine Biosciences can support a higher fair value? The crux lies in compounding revenue assumptions, rising margins and a future earnings base that needs to justify a lower projected multiple than today. Curious which specific growth and profitability paths need to play out to reach that outcome? The full narrative lays out the numbers behind that $192.88 figure.

Result: Fair Value of $192.88 (UNDERVALUED)

However, investors also need to weigh execution risks for Neurocrine Biosciences, including pricing pressure around INGREZZA and the portfolio’s heavy reliance on a few key drugs.

Another View: What Multiples Say About Neurocrine Biosciences

The SWS narrative fair value has Neurocrine Biosciences looking 18% undervalued, but the current P/E of 23.8x tells a tighter story. It sits above the US Biotechs industry at 16.5x and above peers at 21.6x, while the fair ratio sits at 26.1x. Is this a cushion or a warning sign if sentiment shifts?

To see how that P/E gap could close in either direction and what it may mean for risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and caution around Neurocrine Biosciences feels familiar, treat it as a prompt to act promptly and review the data yourself, including the 4 key rewards

Looking for more investment ideas beyond Neurocrine Biosciences?

If Neurocrine Biosciences has sharpened your focus, do not stop here. Fresh stock ideas often come from comparing strong stories against what else the market is offering.

• Spot potential value opportunities early by scanning the 45 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Prioritize resilience and capital preservation by reviewing the 66 resilient stocks with low risk scores to find companies with more measured risk profiles.
• Hunt for underfollowed opportunities using the screener containing 20 high quality undiscovered gems and see which companies with solid fundamentals are still off most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.